Peter Blume-Jensen - Aug 21, 2023 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role: President and CEO, Director
Signature: /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Stock symbol: ACRV
Transactions as of: Aug 21, 2023
Transactions value $: $0
Form type: 4
Date filed: 8/23/2023, 04:19 PM
Previous filing: Jun 1, 2023
Next filing: Nov 16, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRV	Common Stock	Award	$0	+494K	+20.55%	$0.00	2.9M	Aug 21, 2023	Direct	F1
holding	ACRV	Common Stock						321K	Aug 21, 2023	See footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 1/3rd shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in eight equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
F2	These securities are held by co-founder and EVP, Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Content

These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 1/3rd shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in eight equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

These securities are held by co-founder and EVP, Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.